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Executive Summary 
Background: A majority of patients under age 65 face high and increasing out-of-pocket medication costs that interfere with their 
treatment. When polled separately, most physicians and patients report an interest in better addressing drug costs and affordability 
issues, but only a small percentage of physicians know the prices of medications or discuss affordability with their patients. This may 
be due to the fact that drug prices are not transparent to prescribers  or patients and that out-of-pocket costs for insured patients 
can vary widely.  
Objective: We investigated primary care physicians’ interest in a model web-based comparative drug pricing resource designed to 
create transparency of drug prices and (for Medicare D only) out-of-pocket costs. The study objectives were to: 
(1) Explore the factors affecting prescriber communications with patients on selection, costs and affordability of prescription 
drugs.   
(2) Assess the appeal and potential utility of a model comparative drug price resource in improving shared decision-making 
between prescribers and patients. This resource presents real-time prices for brand-name and generic medications at 
pharmacies in specific ZIP codes, allowing patients and prescribers to shop for lower-priced drug products. 
Methods: Eight in-depth qualitative telephone interviews with primary care physicians were followed by an on-line quantitative 
survey of forty primary care physicians. Physicians were randomly selected but screened to include only those expressing a high level 
of concern (eight or higher on a 10 point scale) about patients’ ability to pay for their medications. Participants took the survey via a 
website. During the survey, respondents were presented with two screen shots of our model resource, a website detailing retail prices 
for comparable generic and brand-name drugs at local pharmacies. (Figures 1 and 2) 
Results: The physicians in our sample reported discussing drug cost issues regularly with their patients, and spending considerable 
time seeking resources to assist patients with drug affordability. Most respondents helped patients obtain lower costs by prescribing 
generics and providing samples. Drug company promotions, discounts or patient assistance programs were also used. Physicians 
responded enthusiastically to our resource, believing that it would save staff time and increase the efficiency of their practices. More 
importantly, they felt it would facilitate easier discussions of drug costs and affordability, and thus could increase patient 
engagement, reduce non-adherence, and improve patient care.  
Conclusions: Our study suggests that a web-based drug pricing resource would likely be quickly adopted by physicians and other 
prescribers, particularly those who are already concerned about the cost burden that medications pose for their patients. 
Explanations for interest in our resource include: the current lack of transparency in drug prices, and physicians’ desire to be engaged 
with their patients around affordability of their prescription drugs [1]-[3]. Further, our results suggest that use of such a resource 
could provide valuable improvements to provider-patient engagement, and ultimately result in improved care, while also lowering 
costs. 
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Background 
Health care and medication costs 
In 2010, nearly $2.6 trillion was spent on health care in the 
U.S., an average of $8,402 per person, with a staggering 12 
percent of these total expenditures paid by consumers 
directly [4]. At 3.9 percent a year, the rate of growth in health 
care costs continues to outstrip the overall growth of the 
economy, increasing the costs for consumers, employers and 
government. A 2012 Kaiser Tracking Poll found that more 
than half of Americans said their families cut back on medical 
care due to cost concerns in the previous year [5]. 
 
Prescription drug expenses are widely reported to be a tenth 
of overall health care expenses, or about $260 billion in 2012. 
However, that share rises to 17 percent if prescription drugs 
used in physicians’ offices, hospitals, clinics and other 
settings, as well as over-the-counter and non-prescription 
drugs, are included [6]. 
  
In 2010, consumers paid about 20 percent of the cost of 
prescription drug expenses, significantly above the average 
12 percent contribution for other health care services [7]. 
Those who incurred any prescription drug expenses (about 
two-thirds of Americans) paid on average $1,302 per person 
[8]. However, those families and individuals that used more 
than the average number of prescription drugs—such as 
seniors and people with chronic diseases—were confronted 
with much higher than average costs, and those who were 
uninsured were forced to either pay the full cost or go 
without their medication. For example, uninsured non-elderly 
adults (aged 18-64) surveyed in 2012 were more than twice 
as likely as those with insurance to say that they could not fill 
a prescription or that they had skipped doses [5]. 
 
An individual patient’s cost burden for prescription drugs is 
dependent upon a number of inter-related factors: whether 
they have insurance, how their insurer structures “cost-
sharing” or out-of-pocket costs for prescriptions, the number 
of drugs they are prescribed, which drugs are selected by 
their prescriber, and the actual retail costs of those drugs.  
 
The number of drugs prescribed in the U.S. has climbed 
steadily for decades, with outpatient prescriptions rising from 
1 billion in 1970 to more than 4.1 billion in 2008. The sharpest 
rise occurred from 1997 to 2008, which may be due to several 
factors, including the development of new drugs for 
previously untreatable conditions such as HIV, expanded 
treatment guidelines for certain conditions, such as high 
cholesterol, and promotional marketing to patients and 
physicians. For instance, direct-to-consumer advertising 
(DTCA) rose dramatically after FDA relaxed advertising 
regulations in 1997 [6]. In 2008, the industry spent $4.4 
billion on DTCA [9]. 
 
Advertising and promotions to physicians have also risen 
dramatically; from $3.5 billion in 1996 to $6.6 billion in 2009 
(this excludes samples, valued at $15.9 billion when last 
documented in 2004). Some investigators estimate the total 
promotional spending by industry to be much higher, at $57.5 
billion per year [10]. Marketing has an effect not only on the 
volume of prescriptions written, but also the types of drugs 
prescribed, because industry promotes the newer, more 
expensive brand-name drugs and not older, better 
established drugs, which are mostly generic. 
 
Finally, the average prescription price has increased from 
$22.06 in 1990 to $71.69 in 2008, nearly twice what it would 
have been ($35.90) if the price had risen at the same rate as 
the consumer price index (CPI). Brand-name drugs are far 
more costly than generics, averaging $137.90 per brand-
name prescription vs. $35.22 for generics in 2008 [6]. As a 
result, while generics now account for 80 percent of 
prescriptions, they make up only 27 percent of total spending 
on prescriptions. [35] 
 
Burden of medication costs and its impact on adherence to 
treatment  
Medication adherence refers to the “extent to which the 
patient’s action matches the agreed upon recommendations” 
and has come to be adopted as a less paternalistic term than 
medication compliance, or the “extent to which a person’s 
behavior coincides with medical or health advice [11].” While 
we use the term adherence in this paper, we note that an 
even more patient-centric concept, "concordance", has been 
recommended by some. Concordance suggests "that the 
work of the prescriber and patient in the consultation is a 
negotiation between equals and... [t]he aim is a therapeutic 
alliance between them...” [12].  As we discuss later, such 
shared decision making may be important to successful 
prescriber-patient communication about costs. 
 
Lack of adherence to long-term pharmaceutical treatment 
regimens undermines the effectiveness of medical care. The 
World Health Organization found that adherence to long-
term therapy for chronic illnesses in developed countries 
averaged just 50 percent, with even lower rates in developing 
countries. Solving the problems faced by patients in adhering 
to medication therapy means addressing a number of 
interrelated barriers, including “social and economic factors, 
the health care team/system, the characteristics of the 
disease, disease therapies and patient-related factors”[13]. 
The overall cost burden of medications can play an important 
part in whether patients can or will take medications they are 
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prescribed. Non-adherence with drug therapy is associated 
with many factors, including limited income, serious or 
chronic health conditions and/or the extent of cost shifting to 
patients through high co-pays or deductibles, formulary 
restrictions or outright caps on coverage [14]-[18]. Thus, for 
patients facing these challenges, the prescriber’s selection of 
expensive brand-name drugs over low-cost generics can 
significantly reduce adherence to treatment. 
 
Cost burdens are highest for patients without insurance. 
However, patients who are underinsured or are exposed to 
high levels of cost sharing can also struggle to adhere to 
treatment. Nearly all commercial health insurance is designed 
to facilitate the selection of lower cost, higher value 
medications through the use of policies such as tiered 
formularies with higher co-pays for brand-name drugs, prior 
authorization for brand-name drugs, or step therapy 
(beginning therapy with the lower-cost alternative). For 
patients with fewer health care needs, these policies can, 
with appropriate protections, facilitate the choice of 
evidence-based therapies. However, policies imposed by 
some insurers—benefit caps or limits on the number of 
medications allowed each month, etc.—can leave patients 
without coverage for needed prescriptions, leading to non-
adherence and increased use of other health care services 
[18], [19]. 
 
A synthesis of 132 articles from 1985-2006 on the impact of 
changes in insurance benefit designs found that increases of 
10 percent in patient costs were associated with a 2 percent 
to 6 percent decline in prescription drug use or expenditures. 
However, the impact of patient cost sharing varied by patient 
characteristics, such as income and clinical condition. 
Increased cost-sharing for chronically ill patients (such as 
those with congestive heart failure, lipid disorders, diabetes 
and schizophrenia) was associated with reduced use of 
medications and greater use of inpatient and emergency 
medical services [18]. In contrast, with reduced cost-sharing 
for selected chronic conditions, adherence to medication was 
found to improve by 3.1 percent, while overall health care 
costs were stabilized or declined [20]. 
 
Prescriber– patient communication about medication costs 
A 2011 Consumer Reports survey of primary care providers 
found that “non-compliance with advice or treatment 
recommendations” was the top complaint doctors had about 
their patients, and thirty-seven percent thought it negatively 
affected their ability to provide quality care “a lot” [25]. As 
the authors point out, however, patients face many 
challenges in following treatment recommendations. Indeed, 
in a subsequent survey of patients, Consumer Reports found 
that half of the consumers surveyed who took any 
prescription drug had faced difficulty affording their out-of-
pocket costs. Yet most of these consumers did not feel 
comfortable discussing their difficulty affording medications 
with either their doctors (48 percent) or pharmacists (68 
percent) [36].  
 
Despite the negative effect of medication cost burdens on 
patient adherence, most physicians know little about drug 
prices or differences in price among competing therapies. 
This limits physicians’ ability to advise patients about drug 
costs and work with them to address affordability. Physicians 
report that patients are also frequently unaware of the costs 
of medications prescribed [1], [2], [17], [21]. A substantial 
proportion of patients also report being uncomfortable 
discussing—with either their prescribing doctors or their 
pharmacists—their inability to afford medications [22]. Yet 
physicians, other prescribers, and pharmacists are the experts 
that patients should be able to rely upon to help them reduce 
their monthly out-of-pocket cost burden. 
 
Given limited knowledge about drug costs by both providers 
and patients, it is not surprising that discussions between 
patients and prescribers about the costs of medications rarely 
occur. In one survey of general internists and their patients, 
only 35 percent of physicians and 15 percent of patients ever 
discussed patients’ out of pocket costs [22]. Yet other 
research shows that physicians want to know more about 
costs, and both patients and physicians express a desire to 
engage with each other more frequently about out-of-pocket 
costs [1], [2], [24].  
 
Methods 
We conducted a pilot study of primary care physicians to 
explore the factors affecting their communication with 
patients about drug prices and affordability. We also assessed 
the appeal and utility of a model web-based drug pricing 
resource to facilitate communication and enhance shared 
decision-making between providers and patients. The model 
drug pricing resource provided price comparisons between 
one group of widely prescribed medications (statins), at 
various pharmacies within specific ZIP codes, allowing 
prescribers to more clearly understand the cost impacts of 
their drug selection.1 
 
This model resource was designed for hypothetical use by 
prescribers and patients. While patient engagement is a 
1 Our model resource was constructed based on a combination of 
key features available in two current online resources -- up-to-date 
local retail drug price information from www.GoodRx.com, provided 
in the context of therapeutic recommendations modeled after from 
Consumer Reports Best Buy Drugs. See Appendix C for a comparison 
of existing websites that provide drug price information. 
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critical component of appropriate and effective treatment, 
physicians and other prescribers have the clinical expertise, 
and are ultimately responsible for authorizing any 
prescription. By contrast, patients have superior knowledge 
about their personal financial situations and abilities to pay 
for drugs, which impacts adherence to the prescriber’s 
recommendations. In this study, we sought to understand 
how such a model resource might increase physician 
awareness of the actual costs of medications, and their 
impact upon patients’ cost burdens. We explored whether 
having this information could facilitate better communication 
with patients about their cost burdens, potentially reducing 
cost-driven non-adherence.  
 
The proposed questions of interest were:  
• Whether and how do prescribers currently 
communicate with their patients about the prices of 
medications, or the patient’s ability to pay for them?  
• How open are prescribers to engaging with patients 
on out-of-pocket or overall drug costs as part of 
shared decision-making? 
• What strategies would prescribers use to discuss 
retail drug costs with patients? 
• How valuable is accurate, real-time prescription drug 
cost data to prescribers? 
• How likely would it be that a drug pricing internet 
resource could facilitate prescriber initiation of this 
communication process, increased consumer 
engagement, and more effective decision-making? 
• What barriers, if any, exist to prescribers using such 
a resource with patients? 
• Are there characteristics of such a resource that 
might make it most useful to prescribers and 
patients? 
 
We developed the final study design, qualitative interview 
protocol, and Internet survey in collaboration with Medical 
Marketing Research, Inc. (MMRx), and MMRx conducted the 
interviews and survey. The qualitative phase of eight in-depth 
telephone interviews was conducted with primary care 
physicians. The results were summarized and used to design 
the Internet-based quantitative survey of 40 primary care 
physician respondents.   
 
Sample 
Since studies have shown that most physicians rarely discuss 
drug costs or affordability with their patients, we selected a 
sample of primary care physicians who were more likely to 
engage frequently with patients. Our assumption was that, 
without this selection, the small size of the pilot study sample 
would yield too few physicians with interest or experience in 
addressing cost and affordability issues, and thus we would 
not be able to gather detailed information on the dynamics of 
these physician-patient communications about drug costs, or 
the potential utility of our model resource.  We also selected 
physicians who were in practice less than twenty years, to 
mitigate the potential for variation based on age in our small 
sample.  
 
We screened and selected primary care physicians who self-
reported (1) a high level of concern for the cost of 
prescription medications prescribed for their patients and (2) 
that they work in practices with a preponderance of middle 
class and lower middle class/working poor patients who were 
not on Medicaid.2  
 
Qualitative Telephone Interviews 
Eight primary care physicians were screened and recruited for 
inclusion in the qualitative phase from a total of two hundred 
potential candidates randomly selected from MMRx’s 
proprietary database of 10,000 primary care physicians. 
Respondents were paid an incentive of $60 and participated 
in a one-on-one telephone interview of approximately 30 
minutes in duration. 
 
During each interview, a physician was given a link to two 
hypothetical Internet sites labeled ‘Concept 1’ and ‘Concept 
2’, as shown in Figure 1 and Figure 2 respectively, that 
presented comparative drug price information. Following 
exposure, participants responded to questions regarding 
likely usage of the comparative price resource and the 
advantages it may offer in patient care. (See Appendix A for 
the Interview Protocol.)  
 
Follow-Up Survey 
Forty online surveys were completed by respondents over the 
course of five days.  Respondents were again randomly 
recruited to participate from MMRx’s PCP data base of 
10,000 primary care physicians, using the screening criteria 
above. Approximately 6,000 contacts were made, and 219 
physicians attempted to complete the survey. Of these, 13 
dropped out for no particular reason and 179 did not meet 
the screening criteria because they:  
• were in other specialties (36) 
• spent less than 50 percent of their time in 
clinical practice (3) 
• were in practice for more than 20 years (55) 
• were concerned with the cost of drugs 
prescribed only 1-7 on a 10 point scale (22) 
• were over quota for the region (5) 
2 Medicaid cost-sharing levels are typically nominal for all covered 
medications; thus these patients were likely to be less sensitive to 
differences in co-pays because the differences are small.  
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Participants visited a web-based survey site. (See Appendix 
B.) During the course of the survey, respondents were 
presented links to two additional websites hosting variations 
of our model drug pricing resource. These were labeled 
‘Concept 1’ and ‘Concept 2’, as shown in Figure 1 and Figure 2 
respectively. 
 
Concept 1 was a screen shot of a hypothetical website that 
would provide information on comprehensive retail prices for 
brands and competing generic therapeutic alternatives, at 
different pharmacies within a 25-mile radius of a selected ZIP 
code. (Drugs in the statin class were used in this 
demonstration, with prices for 30 pills of a uniform 20 mg 
dosage). The survey introduced Concept 1, asking 
respondents to make the following assumptions about the 
functional utility of the model resource:   
 
“Assume that a resource could be made available 
that showed you information about the costs of 
brand-name and generic drugs at specific 
pharmacies within a Zipcode, and it allowed you to 
include all other pharmacies within a 1, 5, 10 or 20 
mile radius of the Zipcode.   
 
Assume that the resource could provide the actual 
costs of all doses of a drug, allowing you to compare 
prices for that drug at different pharmacies.  
 
Also assume that the resource would include the 
names and prices of lower cost competing 
therapeutic alternatives in the same therapeutic 
class.  
 
Assume that these alternatives were chosen by an 
independent scientific advisory board, unaffiliated 
with any drug manufacturer, based on reviews of 
available studies.”  
 
Restated, the model resource would provide the actual retail 
costs of brand-name and generic drugs, for all doses, at all 
pharmacies in a 20 mile radius,  including the names and 
prices of lower-cost competing therapeutic alternatives, 
chosen based on unbiased scientific sources. 
 
 
 
Concept 2 presented the same information, but replaced 
retail prices with out-of-pocket co-payments under Medicare 
Part D, in any instances where the copayment is less than the 
retail prices. The introductory text asked respondents to 
assume that the resource would have the same functionality 
as Concept 1 but also allow users to input the name of the 
patient’s Medicare Part D plan to see the expected co-pay 
amount (see survey Q16, Appendix B, for full text).  
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Following exposure to the concepts, participants responded 
to questions regarding the features of this model resource, 
their interest in using it, and the potential advantages it may 
offer in patient care. 
  
Results 
1. Qualitative Interview results  
The responses from the preliminary interviews provided 
additional insights into our two important themes—
prescriber-patient communication and burden of drug 
costs—as well as feedback about the resource. These data 
were used in the design of the quantitative survey. 
 
The eight respondents interviewed were from North Carolina, 
New Jersey, California, New York, Massachusetts, and Florida 
and ranged in experience from 8 to 24 years in practice. 
Three of the physicians interviewed were female, five were 
male. Respondents reported approximately two-thirds of 
patients in their practice were fully insured, and all rated 
their concern about patients’ ability to pay for prescription 
drugs as an 8 or higher on a 10-point scale, where 10 equals 
extremely concerned. 
 
Prescriber-patient communication about medication costs 
Interviewees noted that conversations about drug costs have 
become routine for physicians caring for both low-income 
and higher-income patients: 
“You have to be very open. If you are not willing to 
talk about the difficulties, then the patient may not 
be taking anything. And the physician is then not 
helping the patient’s disease state at all.”  
 
“The initial discussion takes place as I am explaining 
their condition… We look at the patient’s coverage, 
drug stores, websites for coupons, prescription 
cards…” 
 
“When the patients return to my office I ask them for 
concerns/inability to pay. It does not eliminate 
problems with them taking their medication. It’s 
difficult for patients to admit the inability to pay for 
their medications.” 
 
“Cost is always a concern.” 
 
Some physicians interviewed preferred to wait for the patient 
to initiate discussions of cost and affordability:   
 
“I do not normally initiate with every patient. The 
patient talks about difficulty with cost then we take a 
look at their medications and determine a cheaper 
alternative.” 
 
Estimates of how much time each responding physician or 
their staff spend addressing drug costs varied but were 
sometimes substantial:  
 
“I discuss cost about seven to eight minutes with a 
general patient.” 
 
“On average, I spend about one hour a day 
discussing cost with patients” 
 
“My partners and I were discussing this at our last 
meeting, and estimate we each spend at least 30 
minutes a day discussing and/or dealing with cost-of-
medication issues.”  
 
Burden of medication costs and adherence to treatment 
Physicians interviewed reported learning after the fact that 
affordability had been an issue, leading patients to take 
worrisome measures to reduce their cost burden. These 
include failing to fill prescriptions, or taking less than the 
prescribed dose, to stretch out their prescriptions. Additional 
time burdens on physicians and staff also resulted when the 
patient had to ask the pharmacy to call to replace a 
prescription the patient could not afford.  
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“Some medications are cut in half but may not be as 
effective, may take every other day, make some 
medications last 60 days instead of 30 days, take 
their spouse’s medication, or use medications only 
days that it’s needed.” 
 
“Fifteen to 20 times per month I have patients who 
do not get their medication because it’s too 
expensive. Another 15 to 20 times, I have to field 
pharmacy requests to prescribe a cheaper 
medication.” 
 
Some physicians interviewed reported using the limited price 
information they have to inform patients about drug prices, 
or taking additional steps to gather more information. They 
also attempted to assist patients in a number of ways, 
including offering samples, prescribing longer supplies, 
prescribing combination products, writing for generics, or 
recommending discount programs at local retailers or 
pharmacies.   
 
“We look for what’s best for the patients. I will tell 
patients where to get the cheapest medications. I 
also have one of my employees call pharmacies and 
check prices.” 
 
“We try to stick to the Target $4 list as much as we 
can, co-pay cards, supplement with samples.” 
 
“Reps will give us a list of the cost of brand name 
products at local pharmacies.” 
 
Response to specific characteristics of the on-line resource 
and suggestions for its design 
After reviewing a description and screenshot serving as a 
representative sample of a model drug pricing resource, all 
participants responded favorably. They predicted that such a 
resource would be “very useful” for providers, their staff, and 
patients themselves:  
 
“Assuming it’s easy to use, I would use it 10 times a 
day.” 
 
“This may save some time. My assistant can easily 
bring this up and call the prescription in after telling 
the patient the cost.” 
 
“It’s a great idea.” 
 
“I will use this tremendously because it is doing the 
work for me. This is one source compared to many 
sources.” 
“My staff and I will go over this with patients. I’d also 
give the website to patients.” 
 
“If this was available, I would use it today.”  
 
Interviewees felt this model resource could save time by 
addressing out-of-pocket costs up-front during the patient 
visit, rather than later on the phone with pharmacists and 
patients seeking a switch to more affordable drugs. Those 
physicians who report routinely surveying local pharmacies to 
gather price information felt this model resource would save 
time by replacing those efforts.  
 
Some suggested the model resource could be enhanced by: 
• integrating insurance coverage and copay amounts 
• providing address and contact information for 
pharmacies 
• highlighting lowest cost options 
• making it available on a mobile device 
 
Potential drawbacks or limitations regarding this resource 
dealt with the time necessary to use it and the potential 
challenges in integrating it with existing but non-standardized 
electronic systems:  
 
“It will give the patient a choice, it will save the 
patient money, it’s a useful tool, but it also adds to 
our everyday duties.” 
 
“It needs to be customizable to patients’ insurance 
plan. All insurance plans (even with the same 
provider) are not the same.” 
 
“This should be linked to the e-prescribing link. Then 
it could be readily available for the patient.” 
 
“Multiple practices would have different e-
prescribing platforms.” 
 
“The same equipment must be used generally to 
work with any and all e-prescribing platforms.” 
 
“This would not have to be linked with e-
prescribing.” 
 
Still, interviewees that saw its limitations were still receptive 
to working around those barriers:  
 
”The barriers are technical problems, data could be 
lost, patients could hack in, everybody is not 
computer literate, some patients can’t afford a 
computer. Overall, though, my feelings are positive.” 
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“I wish I had the unlimited time to spend with every 
patient, but only in an ideal world. I would be more 
than willing to give this information to patients, but I 
would utilize it only about 5 percent of the time in my 
patient interactions, not every patient and every 
drug.” 
 
“I would use this with five patients a day with the 
flexibility to be adjustable with insurances. I would 
use this with two patients a day without the 
flexibility to be adjustable with insurances.” 
 
Finally, if the resource were to include copay information just 
for Medicare Part D beneficiaries, but not members of other 
plans, interviewees thought the resource would still be 
useful. 
“Even though the site will host only Medicare Part D, 
the patient will still be able to choose the cheaper 
medication.” 
 
“I might have more of a soft spot for that age 
population. I may help them out more.” 
 
“This will be useful because of the doughnut hole, 
period.” 
 
Some felt that the resource could impact cost, efficiency, and 
even adherence:  
 
“Extremely efficient, cost effective, save on time, 
increase compliance because the patient will know 
the cost and will take the medicine.” 
 
2. Quantitative Survey Results 
As described above, 40 online surveys were completed by 
primary care physicians. The characteristics of these 
respondents were:  
  
• Primary Care Physician (n = 40) 
• Percent of professional time spent in clinical practice 
(mean = 94 percent; S.D.=8.72) 
• Years in practice (mean = 1; S.D.=3.34) 
• Level of concern on a ten point scale (1=not 
concerned, 10=extremely concerned) with the cost 
of prescription medications prescribed for patients 
(mean = 8.95) 
• Gender: Male (30), Female (10) 
• Region: Northeast (11), Midwest (11), South (10), 
West (8) 
• Practice Type: Single specialty group practice (16), 
Multi-specialty group practice (13) Solo practice (11) 
• Practice Demographics:  Middle class (49.5%), 
Lower-middle class/working poor (30.2%)), Upper 
class (16.6%).   Patients speaking Spanish as a first 
language were 13.3% of these practices. 3 
 
Prescriber-patient communication about medication costs 
Respondents reported seeing an average of 30 patients a day 
in their practices, and discussing the cost of prescription 
medication with an average of 13 patients a day (43 percent). 
Total cumulative time spent on these discussions was 
estimated to be an average of 1 hour per day of physician 
and/or staff time. (Table 2)  
 
Half of the survey respondents found it relatively difficult to 
engage patients in discussions concerning the cost of the 
medications they prescribe. Fifty percent of respondents 
rated the difficulty as six or higher on a 10 point scale. At the 
same time, 50 percent of respondents found discussions of 
drug costs to be comparatively easier, rating the difficulty as 
a five or lower, yielding a bi-modal distribution. (Table 4) 
 
One open-ended question asked respondents how issues 
concerning the cost of medications, or their patients’ abilities 
to afford or access their medications, are raised when such 
discussions do occur. Responses included: the physician asks 
patients if they can afford their medications (32.5 percent); 
asks patients if they have had any problems getting or taking 
their medications (17.5 percent); or asks patients if they have 
prescription drug coverage (7.5 percent). Respondents also 
report that patients bring up the issue about 30 percent of 
the time, often as a complaint about the cost of medication. 
(Table 5) Overall, it appears that both patients and physicians 
raise this issue directly and indirectly, but that physicians 
initiate these discussions in nearly twice as many different 
ways as their patients do.  
3 We included this query given that Spanish-speaking 
Latina/os constitute a disproportionately large segment of 
the uninsured and lower income population – in 2013, 33% of 
Hispanics lack of insurance coverage, compared to 19% of the 
U.S. population overall. And many Latinos will likely remain 
uninsured, despite the recent increases in enrollment under 
the ACA in early 2014, because more than half (51%) of 
Hispanic uninsured adults have incomes at or below the 
Medicaid expansion limit, and thus will fall into the Medicaid 
Gap if living in states that do not expand Medicaid. See Kaiser 
Family Foundation (2013) Issue Brief: The Impact of the 
Coverage Gap in States not Expanding Medicaid by Race and 
Ethnicity. Available: http://kff.org/disparities-policy/issue-
brief/the-impact-of-the-coverage-gap-in-states-not-
expanding-medicaid-by-race-and-ethnicity/. Accessed 20 May 
2014. 
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Physicians reported that they use many types of information 
to answer patient questions concerning the cost of 
medications. These include cost information from local 
pharmacies or pharmacists (30 percent), formulary 
information provided by insurers (20 percent), and cost 
information from drug company sales representatives (20 
percent). Respondents gained cost information from 
government or other websites 10 percent of the time and 
from the Epocrates handheld app 10 percent of the time. 
(Table 6) 
 
Burden of medication costs and its impact on adherence to 
treatment 
Respondents reported encountering situations of non-
adherence to treatment due to the cost of medication 
frequently—an average of 26 times per month patients had 
not filled a prescription and 28 times per month patients 
were taking less than the prescribed dose due to costs.  
(Table 3) 
 
In response to an open ended question about current 
strategies respondents are using to reduce the cost of 
medications for some or all of their patients, the top two 
strategies were prescribing generics (60 percent) and giving 
free samples to patients (40 percent). To a lesser extent 
respondents used drug company patient assistance programs 
(17.5 percent), coupons and rebates (17.5 percent), as well as 
similar cost reduction cards and vouchers. Five percent 
recommended that patients split pills and only 5 percent 
explicitly mentioned using the $4/$12 drug lists available at 
some pharmacies. (Table 7) 
 
Response to the model web-based drug pricing resource 
More than 80 percent of respondents had a positive response 
to the web-based drug pricing resource, with just one 
respondent having a negative response. (Table 8) Ninety 
percent said they would use the resource, and 35 percent 
thought they would use it frequently. (Table 11) On the 
whole, physicians predicted that using this resource would 
significantly reduce cost-related barriers to adherence. Eighty 
percent thought it would substantially (seven or higher on a 
10 point scale) reduce how often patients failed to fill their 
prescriptions due to cost, and 70 percent predicted it would 
significantly reduce how often patients did not take their 
medications. (Table 14b, 14c) In addition, 90 percent of 
respondents predicted this resource would be moderately to 
extremely useful (seven or higher) in making it easier to 
engage with patients in a discussion of cost and affordability 
of medications. (Table 15) Respondents anticipated the 
resource would be used almost equally by physicians (with 
their patients), by staff or nurses, and by patients themselves. 
(Table 12) Furthermore, 90 percent of respondents stated 
that they would use it “often” to “frequently” (seven or 
higher, Table 11) and perhaps as much as ten times per day. 
(Table 13) The majority of respondents felt it had the 
potential to reduce the amount of time they spend 
addressing their patients’ issues with medication costs, either 
time spent directly with patients or with third parties, such as 
pharmacies and payers. Sixty percent predicted a large time-
saving impact (greater than eight on a 10 point scale).    
(Table 14a) 
 
While respondents gave the model resource high ratings on 
all its features, they found that the comparisons of prices of 
the same drugs at different pharmacies, as well as 
comparisons of the prices of brand name drugs and lower 
cost generic alternatives, to be most useful. (Table 9a, 9b, 9c) 
Almost half of the respondents (42.5 percent) thought it 
would be extremely important for the resource to include 
information on co-pays for ALL insurance plans, not just 
Medicare Part D, and 85 percent thought this additional 
feature would be at least moderately important. (Table 16) 
But even a resource with only Part D co-pay information 
would reportedly be used nearly as often as a resource with 
all insurance co-pay information. (Table 13) 
 
When asked what, if anything, they particularly disliked about 
the model drug pricing resource presented in Concept 1, a 
vast majority of respondents, 70 percent, answered 
“nothing.” The most commonly voiced negative opinions 
were that it could be time-consuming (10 percent) and that it 
provided too much information (7.5 percent). (Table 10) 
Finally, half of the respondents thought it would be extremely 
important to have the resource available as an app for a 
mobile device (Table 17), and 75 percent saw this as at least 
very important (seven or higher).  
 
Discussion  
Prescriber-patient communication about medication costs 
and impact on adherence 
Primary care physicians surveyed in this study frequently 
encountered situations in which high out-of-pocket drug 
costs impacted adherence. In these circumstances, they 
reported that their patients either did not fill a prescription or 
took less than prescribed. Previous studies show that when 
patients cannot afford their medications, they may be unable 
to initiate or continue drug treatment, which can compromise 
quality of care and increase the patient’s need for other, 
more expensive services, such as hospitalization [16], [18].   
 
Because our sample of physicians only included those most 
interested in addressing the cost burden upon their patients, 
our findings understandably differ with broader surveys of 
providers in some respects. While all physicians in our pilot 
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study discussed drug costs with patients, a study of internists 
and patients regarding beliefs and experiences of medication 
use found that just 35 percent of physicians and 15 percent of 
patients had ever discussed costs, even though the need was 
clear, since one-third of patients reported being burdened by 
drug costs [2]. Similarly, a 2011 survey found that only 15 
percent of the physician respondents had discussed out-of-
pocket medication costs frequently with patients [24]. The 
results in our pilot study more closely match those of a study 
of provider communication with senior patients, a group with 
high health care and prescription drug needs, and lower than 
average incomes. In that study, nearly half of the physicians 
reported that they discussed costs with at least half their 
senior patients in the previous month [27].    
 
Studies do show, however, that a majority of doctors feel a 
professional obligation to both discuss drug affordability with 
their patients, and to consider costs when writing 
prescriptions [1]. Seventy-nine percent of the internists in the 
study cited above desired to discuss out-of-pocket costs  with 
patients, while 91 percent of the physicians in the 2011 
survey thought it was important to manage patient’s out-of-
pocket costs  [24].  
 
If physicians report such a widespread sense of professional 
obligation to address costs with their patients, what are the 
barriers to such communication? Even among our 
respondents, half rated the difficulty of undertaking these 
discussions as six or higher on a 10 point scale. Earlier studies 
confirm that doctor-patient communication about medication 
costs is difficult and can be affected by many factors, 
including available information, relationships (e.g. trust, 
satisfaction, commitment), patient variation (e.g. attitudes, 
beliefs, condition, coverage), practitioner variation (e.g. 
attitudes, beliefs, expertise, practice organization) and role 
expectations (e.g. socially expected behavior in this 
prescribing process) [28].   
 
Reliable, accessible information on drug prices could address 
one of the above barriers to good communication and 
perhaps increase trust between patient and provider as well. 
A systematic review of 24 studies found that on the whole, 
physicians were not able to accurately estimate the cost of 
specific drugs. They also consistently underestimated the 
difference in prices between brand-name drugs and generics 
[29]. Not surprisingly, studies show that physician confidence 
in communicating about the costs of medications is 
influenced by their own level of knowledge of these costs. 
Physicians with higher perceived knowledge of drug costs 
were more likely to discuss costs with their patients. [27] 
 
Respondents reported using a number of strategies to lower 
costs for their patients, but some of these strategies may be 
counterproductive. For instance, drug samples that are 
widely distributed by the drug industry are designed to 
promote the newest, most expensive brand name drugs, and 
have been shown to increase patient out-of-pocket costs by 
50 percent on average [26]. Brochures, flyers, coupons and 
vouchers provided by drug companies and sales 
representatives are also intended to market largely expensive 
brand-name drugs, which often compete with equally 
effective, low-cost generic drugs or lower-cost brand name 
drugs that treat the same conditions. 
 
Physicians in our survey spent a substantial amount of time 
each day (one hour on average) addressing issues related to 
medication costs. A common issue is handling requests from 
pharmacists, on behalf of patients filling a prescription, to 
change to a drug with a lower out-of-pocket cost. While it 
may take some time to use a pricing resource before making 
the initial prescribing decision, prescriber workload and 
effectiveness may be reduced if more affordable drugs were 
prescribed initially. For instance, a study of a tiered health 
plan found that patients who were initially prescribed 
generics or a lower cost brand name drug were less likely to 
switch medications later.   Furthermore, the authors 
concluded that clinicians could improve medication 
adherence “by choosing wisely within a drug class and 
prescribing generic or preferred formulary agents when 
initiating chronic therapy” [15]. 
 
While lack of affordability may discourage adherence to drug 
treatment recommendations, some patients may resist taking 
prescribed medicines for more fundamental reasons. A 
synthesis of qualitative studies of medicine-taking found that 
such resistance may occur not because of failings in patients, 
doctors or systems, but because of concerns patients have 
about taking medicines in general and about the safety and 
efficacy of medications that have previously been prescribed 
to them [29]. To address general patient concerns about 
medication, some have proposed that practitioners practice 
“minimally disruptive medicine” [31], taking into account, for 
instance, that non-adherence may be the result of very high 
treatment burdens, especially among those with complex, 
chronic conditions. These burdens include multiple, usually 
uncoordinated providers, and multiple treatment guidelines 
and drug management policies for each chronic condition. 
We would suggest that high, cumulative out-of-pocket costs 
of multiple medications could be an important component of 
such treatment burdens, which prescribers would be better 
able to address if they had access to reliable, evidence-based 
information on medication options and their associated costs.  
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Potential benefits to increased prescriber-patient engagement 
and practice efficiency 
 
Our results suggest that a comprehensive, unbiased online 
resource on drug prices and therapeutic alternatives could 
improve the quality and efficiency of patient care. Foremost, 
such a price transparency resource could easily provide 
prescribers with transparent price information, which would 
(i) increase prescribers’ comfort in initiating and engaging 
discussions of drug cost and affordability issues with their 
patients. In addition, such a resource would (ii) increase the 
staff efficiency in clinical settings, by freeing up time currently 
spent gathering price information, or dealing with pharmacist 
phone calls at the point of service. 
 
Optimally, such a pricing resource would be most valuable to 
prescribers if it provided reliable, automatically updated, 
easily accessible information on drug prices and therapeutic 
alternatives, for use by prescribers or other providers, and 
consumers themselves. However, even less sophisticated 
approaches may provide substantial benefits. However, even 
less sophisticated approaches may provide substantial 
benefits. For instance, another pilot study using an 
educational module found that providing future prescribers 
with very general information on drug prices and therapeutic 
alternatives can have a measurable impact upon future 
prescribers’ confidence in discussing cost and affordability 
with patients. [37].   
 
Broader implications for savings by the health care system 
While further study of robust web-based pricing resources is 
necessary to predict the impact among providers and 
patients more broadly, it is likely that reducing the out-of-
pocket cost burden for patients could also contribute to 
reducing total drugs costs for health plans, and our health 
care system overall. First, if lowering the out-of-pocket cost 
burden increases patient adherence, then other health care 
costs for hospitalization or acute care can be reduced. And 
within the drug market, brand-name drugs have higher copay 
costs, and higher total costs to health plans as well. The 
average difference in price between a brand and a generic 
was $76 per prescription in 2007, but brand and generic 
prices have polarized since then, with brands getting costlier, 
and generics getting cheaper. [38] In this context, reducing 
out-of-pocket costs by using more generic drugs can also 
produce significant savings for our health plans and health 
system overall.  
 
Prior studies have shown this to be true. For instance, one 
study of an electronic prescribing system integrated with a 
clinical decision support system found a significant increase in 
evidence-based new prescriptions, and a reduction in the use 
of high-cost therapies. This resulted in savings of more than 
$850 per member per month in the first year. The system 
included both evidence-based therapeutic recommendations 
and cost comparisons. It did not use “forcing functions, pop-
up windows or other features that directly interfered with the 
prescribing process or required action by the physician. It 
simply described the evidence (and costs) and let the 
physician decide" [33]. Notably, an electronic prescribing 
system without the decision support feature did not result in 
savings. 
 
Conclusions 
Our study indicates that when they occur, current prescriber-
patient discussions about drug costs are time consuming, and 
even physicians who are concerned about the issue do not 
have these discussions with all of their patients, despite 
seeing non-adherence frequently each day. Studies of a 
broader cross-section of physicians have found that few 
discuss costs with their patients, but that most physicians and 
patients would like to address these issues.  
 
Based on our pilot study, we suggest that comprehensive 
web-based drug pricing resources would have multiple 
benefits for both providers and their patients by fostering 
better patient-prescriber engagement, at the point of 
prescribing. Such a resource would provide providers with 
accurate price information for comparison between 
therapeutic options within any therapeutic class. Having 
ready access to this resource may give prescribers the 
confidence to initiate patient engagement, through 
communications about drug costs and affordability. 
Addressing a significant prescriber barrier prescriber-patient 
communication around affordability would likely have 
multiple benefits.  
 
First, it could improve the doctor-patient relationship, by 
facilitating needed discussions about health care costs that 
support the doctor in engaging in prescribing decisions with 
awareness and sympathy for the cost burden faced by their 
patients. Second, it would help foster better prescriber - 
patient engagement and better shared decision-making, in 
the form of making a more effective initial prescribing 
decision. This could improve patient care, through 
prescription choices that would be less likely to be affected 
by cost-related non-adherence decisions by the patient. 
Finally, the resource may reduce prescriber and staff time 
spent investigating low-cost resources for patients, in 
addressing problems with patients who do not take their 
medications due to the cost, and in fielding pharmacy 
requests to prescribe cheaper medications after the initial 
prescription is written.  
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Given the interest among physicians in better engagement 
with patients on the issues of cost and affordability, and the 
current lack of comprehensive, reliable information on retail 
drug prices, our survey suggests that such web-based 
resources on drug pricing would be quickly adopted by 
physicians and other prescribers who are already engaged in 
addressing medication costs. Such resources also have the 
potential to be adopted more broadly, given the research 
showing widespread interest among physicians in discussing 
costs with patients in order to improve prescribing. [1]-[3]. 
After the Affordable Care Act is fully implemented in 2014, 
insurance coverage may expand significantly, but 
undocumented immigrants will undoubtedly continue to face 
barriers to subsidized insurance or Medicaid programs. In 
that context, providing a retail drug price transparency 
resource in Spanish and other languages may be necessary to 
help this particularly vulnerable population access affordable 
medication options.  
 
Using such retail pricing resources would likely lower out-of-
pocket costs for patients. In addition, accessible, unbiased 
information on therapeutic alternatives, including treatment 
profiles and side effects, would be of significant value to 
prescribers, and would be likely to promote health system 
savings overall. Including information on out-of-pocket copay 
costs under various insurance plans would make the 
resources still more effective and valuable.  
 
There are few studies of patient barriers to communicating 
about drug cost burden to their providers, but ample 
evidence that those barriers exist, and could be adversely 
affecting the costs and quality of care that patients receive. 
Further study of how price transparency resources could help 
patients in discussing issues of cost and affordability with 
their clinicians is needed. 
 
References 
1. Alexander GC, Casalino LP, Meltzer DO (2005) 
Physician strategies to reduce patients' out-of-
pocket prescription costs. Arch Intern Med 165: 633-
636. doi:10.1001/archinte.165.6.633. 
2. Alexander GC, Casalino LP, Tseng CW, McFadden D, 
Meltzer DO (2004) Barriers to patient-physician 
communication about out-of-pocket costs. J Gen 
Intern Med 19: 856-860. doi: 10.1111/j.1525-
1497.2004.30249.x. 
3. Shrank WH, Fox SA, Kirk A, et al. (2006) The effect of 
pharmacy benefit design on patient-physician 
communication about costs. J Gen Intern Med 21: 
334-339. doi: 10.1111/j.1525-1497.2006.00402.x. 
 
 
4. Center for Medicare and Medicaid Services (2012) 
National health expenditure projections, 2011-2021. 
Available: http://www.cms.gov/Research-Statistics-
Data-and-Systems/Statistics-Trends-and-
Reports/NationalHealthExpendData/Downloads/Proj
2011PDF.pdf. Accessed 14 Nov. 2013.   
5. Kaiser Family Foundation (2012) Kaiser public 
opinion: Health security watch.  Available: 
http://kaiserfamilyfoundation.files.wordpress.com/2
013/05/8322_hsw-may2012-update.pdf. Accessed 
14 Nov. 2013  
6. Schondelmeyer SW (2009) Recent economic trends 
in American pharmacy. Publ Am Inst Hist Pharm 51: 
103-126. 
7. California HealthCare Foundation (2012) California 
health care almanac. Available: 
http://www.chcf.org/almanac. Accessed 14 Nov. 
2013. 
8. Rohde F (2011) Statistical Brief: Prescription drug 
expenditures in the 10 largest states, 2008. 351 
edition. Rockville, MD: Agency for Healthcare 
Research and Quality. Available: 
http://meps.ahrq.gov/mepsweb/data_files/publicati
ons/st351/stat351.shtml. Accessed 14 Nov. 2013. 
9. IMS Health (2011) Top-line market data 2011: US 
promotional information. Available: 
http://www.imshealth.com. Accessed 14 Nov. 2013. 
10. Gagnon M, Lexchin J (2008) The cost of pushing pills: 
A new estimate of pharmaceutical promotion 
expenditures in the United States. PLoS Medicine 25: 
29-33. doi:10.1371/journal.pmed.0050001. 
11. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X 
(2008) Interventions for enhancing medication 
adherence. Cochrane Database Syst Rev 2: 1-158.  
doi: 10.1002/14651858.CD00001. 
12. Thistlethwaite JE, Ajjawi R, Aslani P (2010) The 
decision to prescribe: Influences and choice. 
InnovAiT 3:237-243. doi: 10.1093/innovait/inp132. 
13. Sabaté E (2003) Adherence to long-term therapies: 
Evidence for action. Geneva, CH: World Health 
Organization.  XIV  
14. Shrank WH, Hoang T, Ettner SL, et al. (2006) The 
implications of choice: Prescribing generic or 
preferred pharmaceuticals improves medication 
adherence for chronic conditions. Arch Intern Med 
166: 332-337. doi:10.1001/archinte.166.3.332. 
15. Huskamp HA, Deverka PA, Epstein AM, Epstein RS, 
McGuigan KA, Frank RG (2003) The effect of 
incentive-based formularies on prescription-drug 
utilization and spending. N Engl J Med 349: 2224-
2232. doi: 10.1056/NEJMsa030954. 
http://z.umn.edu/INNOVATIONS                  2014, Vol. 5, No. 3, Article 174                               INNOVATIONS in pharmacy   12 
 
Oringinal Research PRACTICE-BASED RESEARCH 
 
16. Goldman DP, Joyce GF, Escarce JJ, et al. (2004) 
Pharmacy benefits and the use of drugs by the 
chronically ill. JAMA 291: 2344-2350. 
doi:10.1001/jama.291.19.2344. 
17. Alexander GC, Tseng CW (2004) Six strategies to 
identify and assist patients burdened by out-of-
pocket prescription costs. Cleve Clin J Med 71: 433-
437. doi: 10.3949/ccjm.71.5.433. 
18. Goldman DP, Joyce GF, Zheng Y (2007) Prescription 
drug cost sharing: Associations with medication and 
medical utilization and spending and health. JAMA 
298: 61-69. doi:10.1001/jama.298.1.61. 
19. Soumerai SB (2004) Benefits and risks of increasing 
restrictions on access to costly drugs in Medicaid. 
Health Aff (Millwood) 23: 135-146. doi: 
10.1377/hlthaff.23.1.135. 
20. Choudhry NK, Fischer MA, Avorn J, et al. (2010) At 
Pitney Bowes, value-based insurance design cut 
copayments and increased drug adherence. Health 
Aff (Millwood) 29: 1995-2001. doi: 
10.1377/hlthaff.2010.0336. 
21. Alexander GC, Casalino LP, Meltzer DO (2003) 
Patient-physician communication about out-of-
pocket costs. JAMA 290: 953-958. 
doi:10.1001/jama.290.7.953. 
22. Consumer Reports (2012) Best buy drugs 
prescription drug tracking poll #4. Yonkers: 
Consumer Reports National Survey Research Center. 
23. Shrank WH, Joseph GJ, Choudhry NK, et al. (2006) 
Physicians' perceptions of relevant prescription drug 
costs: Do costs to the individual patient or to the 
population matter most? Am J Manag Care 12: 545-
551. 
24. Consumer Reports (2011) What doctors wish their 
patients knew: Surprising results from our survey of 
660 primary-care physicians. Consum Rep 76:20-23. 
25. Alexander GC, Zhang J, Basu A (2008) Characteristics 
of patients receiving pharmaceutical samples and 
association between sample receipt and out-of-
pocket prescription costs. Med Care 46: 394-402. 
doi: 10.1097/MLR.0b013e3181618ee0. 
26. Beran MS, Laouri M, Suttorp M, Brook R (2007) 
Medication costs: The role physicians play with their 
senior patients. J Am Geriatr Soc 55: 102-107. doi: 
10.1111/j.1532-5415.2006.01011.x. 
27. Schommer JC, Worley MM, Kjos AL, Pakhomov SV, 
Schondelmeyer SW (2009) A thematic analysis for 
how patients prescribers, experts, and patient 
advocates view the prescription choice process. Res 
Social Adm Pharm 5: 154-169. doi: 
10.1016/j.sapharm.2008.07.001. 
28. Allan GM, Lexchin J, Wiebe N (2007) Physician 
awareness of drug cost: A systematic review. PLoS 
Med 4: 1486-1496. doi: 
10.1371/journal.pmed.0040283. 
29. Pound P, Britten N, Morgan M, et al. (2005) Resisting 
medicines: A synthesis of qualitative studies of 
medicine taking. Soc Sci Med 61: 133-155.  doi: 
10.1016/j.socscimed.2004.11.063. 
30. Brownlee S (2007) Overtreated: Why too much 
medication is making us sicker and poorer. New 
York: Bloomsbury USA. 
31. May C, Montori VM, Mair FS (2009) We need 
minimally disruptive medicine. BMJ 339: 485-487. 
doi: 10.1136/bmj.b2803. 
32. McMullin ST, Lonergan TP, Rynearson CS (2005) 
Twelve-month drug cost savings related to use of an 
electronic prescribing system with integrated 
decision support in primary care. J Manag Care 
Pharm 11:322-332. 
33. Stacey D, Bennett CL, Barry MJ, et al. (2011) Decision 
aids for people facing health treatment or screening 
decisions. Cochrane Database Syst Rev (10): 1-207.  
doi: 10.1002/14651858. 
34. Jaspers MW, Smeulers M, Vermeulen H, Peute LW 
(2011) Effects of clinical decision-support systems on 
practitioner performance and patient outcomes: A 
synthesis of high-quality systematic review findings. 
J Am Med Inform Assoc 18: 327-334. doi: 
10.1136/amiajnl-2011-000094. 
35. IMS Institute for Healthcare Infomatics (2012)  The 
Use of Medicines in the United States: Review of 
2011. Parsippany, NJ: IMS Institute for Healthcare 
Infomatics. 
36. Consumer Reports (2012) Sluggish economy forces 
Americans to cut corners to pay for medications.  
Available: 
http://www.consumerreports.org/cro/2012/09/slug
gish-economy-forces-americans-to-cut-corners-to-
pay-for-medications/index.htm. Accessed 13 Nov. 
2013.   
37. Kumar, R., Shah, N, Levy, A, Saathoff, M, Fama, J, 
Arora, V (2012) GOTMeDS? Designing and Piloting an 
Interactive Module for Trainees on reducing drug 
costs.  In: Proceedings of the Annual Meeting of the 
National Physicians Alliance. Poster on file with 
authors.  
38. Congressional Budget Office (Sept. 2010), Effects of 
using generic drugs on Medicare's prescription drug 
spending. pp 15. Available: 
http://www.cbo.gov/publication/21800 Accessed 1 
July 2014. 
 
http://z.umn.edu/INNOVATIONS                  2014, Vol. 5, No. 3, Article 174                               INNOVATIONS in pharmacy   13 
 
Oringinal Research PRACTICE-BASED RESEARCH 
 
  
APPENDIX A 
 
QUALITATIVE INTERVIEW GUIDE 
Patient/Provider Communications Regarding Prescription Prices 
Medical Marketing Research, Inc. for Community Catalyst, 2012 
 
Dr. Name _____________________________ 
 
Thank you, doctor for participating in our study.  Today our interview will focus on the interaction and communication that occurs 
between patient and provider with regard to costs of medications prescribed. Your responses are considered confidential. There are 
no right or wrong answers; we are just seeking your candid thoughts and opinions on the issues we will be discussing. 
 
For the sake of report development, we will be recording this interview. I will start the recorder now. 
 
1. First of all, if you would briefly describe your practice (GROUP/SOLO,  URBAN/RURAL, ETC.). 
2. About what percent of your patients would you say are: Medicaid, Upper Income, Working Poor, Middle Class. 
3. How do you know, learn of, patient’s inability to pay or problems paying for prescriptions? How do you identify these 
patients, and when you do, how does it impact your prescribing? 
4. And about what percent of your patients would you estimate have trouble paying for the prescription medications you 
prescribe? What kind of trouble – how often do you think they don’t get their prescription filled at all? Get only part of their 
prescription filled? Don’t take their medication as directed in order to reduce  costs? What other behaviors have you 
noted patients engaging in to reduce medication costs? 
5. Think for a moment of one of your patients who you knew had difficulty paying for their drugs. With that kind of person in 
mind, how might you communicate with them about the prices of medications and their ability to pay for them. Would you 
initiate the discussion, or wait for them to say something?  Give me an example of how that discussion might go. 
6. In general, how open are you to engaging in discussions with your patients on  the cost of drugs, either their own ability to 
pay the out-of-pocket cost or the issue of the total costs as part of shared decision-making?  
7. Do you use electronic information of any kind currently in your practice to interact with or advise patients? What do you 
use (PROBE FOR EXAMPLES). What about any kind of electronic pricing information concerning medications? 
8. REFER TO SCREENSHOT OF WEBSITE: I want you to assume the availability of an electronic price data website (accessible via 
computer and by  mobile device app) for you/your staff to use in discussions with patients about prescriptions and 
pharmacy location choices. Assume that the site would be quick and easy to use; could be used by yourself, your staff, 
and/or your patients; would contain pricing information on virtually every product you might prescribe, list over 90% of 
pharmacies within a given ZIP code, and would offer: 
 Comparisons by pharmacy of the same generic or brand name drugs; price comparisons of generics vs. their brand 
name equivalents; and information about low cost therapeutic alternatives to brand names that do not have exact 
generic   (E.g. omeprazole as an alternative to Nexium) 
 Availability of price comparisons by drug at all or most pharmacies in the patient’s zip code area, along with mail 
order services 
 Availability of information on insurance plans (E.g. formularies and co-pay tiers)    
9. What specific barriers do you see to the use of such a tool, even with the desired functionalities?  What additional features 
would make it most useful – probe  integration with e-prescribing, integration with other electronic systems? How 
interested would you be in using such a resource? How often do you think you would use it? Why? For what type of patient, 
if any, would you most likely use it? Who would most likely use it – you in direct interaction with patients, your staff in 
direct interaction with patients, patients on their own? Why? 
10. How useful would the site be if it had information on copays and formulary information for Medicare part D only, not 
others?  (E.g. uninsured patients and those whose insurance information was on the site, such as Medicare D)  
11. Overall, doctor, what do you think the value and/or impact of using a tool like this would be? 
12. Thank you for participating in our interview, doctor. Do you have any final advice or recommendations you would like to 
share on this topic?  
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APPENDIX B 
  
Internet Survey of Primary Care Physicians (n=40) 
Medical Marketing Research, Inc. for Community Catalyst, 2012 
 
                                                                                          Questionnaire # ________   
 
Thank you for participating in our study concerning prescription medication costs.  For qualification purposes please answer the following 
questions. 
 
S1. What is your specialty? 
 ______ PCP/GP/IM  
 ______ Other  
 
S2. What percent of your time is spent in CLINICAL practice? 
 % of time spent in clinical practice   ______ 
 
S3. About how many years have you been in practice? 
 Years in practice ______ 
 
S4. On a scale of 1 to 10, 1 meaning not at all concerned and 10 extremely concerned, how concerned are you with the costs of the medications 
you prescribe for patients?   
 
(Used as screening criteria: Those answering 7-10 accepted for sample) 
 
Not at 
All 
Concern
ed 
1 2 3 4 5 6 7 8 9 
Extremel
y 
Concern
ed 
10 
Level of concern            
 
S5. What is your gender? 
 □   Male  
 □   Female  
 
S6. What region of the country do you practice in? 
 □   Northeast  
 □ South  
 □ Midwest  
 □ West  
S7. Are you in a: 
 □ Solo practice  
 □ Single specialty group practice  
 □ Multi-specialty group practice  
 
Q1. About how many patients do you see per day in your practice? 
 Patients seen per day ________ 
 
Q2. Thinking about your interactions, about how many times per day do you engage patients in discussion concerning the cost of medication and 
their ability/willingness to pay for medications you prescribe? 
 Number of times per day ______ 
 
Q3. How much time per day would you estimate you and your staff spend addressing issues related to the cost of the medications you prescribe for 
patients?  This could be talking with patients directly as well as talking to pharmacies or other third parties about patient medication costs.  Please 
give your answer in minutes per day. 
 Minutes per day ______ 
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Q4. How many times per month would you estimate you encounter each of the following situations:  Please answer in number of times per month. 
 Patient has not gotten a prescription filled because of medication cost   
 Patient has taken less than the prescribed dose because of medication cost    
 
Q5. On a scale of 1 to 10, 1 meaning not at all difficult and 10 extremely difficult, how difficult do you find it to engage patients in discussion 
concerning the cost of the medication you prescribe? 
 
 
Not at 
all 
difficult 
1 2 3 4 5 6 7 8 9 
Extremel
y 
difficult 
10 
Level of difficulty            
 
 
Q6. When you talk with patients about the cost of their medications, how does the conversation get started? 
 
Q7. What, if any, resources do you have available to you to answer patient questions concerning the cost of medications you are prescribing? 
 
Q8. What strategies do you currently use to lower the cost of medications for some or all of your patients? 
 
Please read the following concept statement.  Once you have finished reading please click on the link below to view some pricing information 
relevant to this concept.  
 
“Assume that a resource could be made available that showed you information about the costs of brand-name and generic drugs at 
specific pharmacies within a Zip code, and it allowed you to include all other pharmacies within a 1, 5, 10 or 20 mile radius of the Zip code.   
Assume that the resource could provide the actual costs of all doses of a drug, allowing you to compare prices for that drug at different 
pharmacies.  
Also assume that the resource would include the names and prices of lower cost competing therapeutic alternatives in the same 
therapeutic class.  
Assume that these alternatives were chosen by an independent scientific advisory board, unaffiliated with any drug manufacturer, based 
on reviews of available studies.”  
 
Link:  Concept-1  (Screenshot of hypothetical website) 
Q9. In general, would you describe your reaction to this concept as: 
   Positive  
   Negative  
   Neutral  
 
Q10. Which of the following features, if any, do you like or find most useful? 
 
 
Not 
Useful 
1 2 3 4 5 6 7 8 9 
Very 
Useful 
10 
Recommendations of 
generic alternatives to 
brand-name drugs?  
          
The difference 
between the price of 
brand-name drugs 
and lower cost 
generic alternatives?  
          
The differences in 
exact prices for the 
same drug at different 
pharmacies?  
          
 
Please list any other features you would find useful.  If you have no additional features to list please leave blank and click the continue button at 
the bottom of the page to proceed to the next question. 
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Q11. What if anything do you particularly dislike? 
 
Q12. On a scale of 1 to 10, 1 meaning would not use at all and 10 meaning you would use it frequently, how often would you expect to use this 
resource: 
 
 
Would 
Not Use 
at All 
1 2 3 4 5 6 7 8 9 
Would 
Use it 
Frequen
tly 
10 
Frequency of use            
 
 
Q13. There are multiple ways this information can be shared with patients - through you personally, through your staff, by letting the patient 
access the information themselves.  Of the times you would use this resource, what percent of the time do you think you would: 
 a. Personally use it with patients  ............................................................................................................   ______ 
 b. Have your staff use it with patients  ....................................................................................................   ______ 
 c. Let patients know about it and let them access it themselves  ............................................................   ______ 
 
Q14. If this resource were available to you, how many times per day would you estimate you might use it in some way in discussing the cost of 
medication with your patients? 
 Times per day    ______ 
 
 
Q15. On a scale of 1 to 10, 1 meaning no impact at all and 10 meaning a great impact, what impact would you expect your use of this resource to 
have on: 
 
 
No 
Impact 
at All 
1 2 3 4 5 6 7 8 9 
A Great 
Impact 
10 
a. Lowering the 
amount of time spent 
per patient addressing 
cost issues from 
patients and third 
parties like 
pharmacies and 
payors:  
          
b. The frequency with 
which patients do not 
get their prescriptions 
filled due to price 
issues:  
          
c. The frequency with 
which patients do not 
take their medication 
as directed due to 
cost issues:  
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Q16. On a scale of 1 to 10, 1 meaning not useful at all and 10 meaning extremely useful, how useful do you feel such a resource would be in making 
it easier to engage with your patient in a discussion of cost and affordability of the medications you prescribe?  
 
 
Not 
Useful at 
All 
1 2 3 4 5 6 7 8 9 
Extremel
y Useful 
10 
Level of usefulness            
 
 
Please read the following concept statement.  Once you have finished reading please click on the link below to view some additional pricing 
information relevant to this concept.  
 
“Assume, as before, that a resource could be made available that showed you the same information as above, but it also allowed you to 
input the name of your patient’s Medicare Part D plan, in order to see the expected co-pay amount.   In some cases, a pharmacy may sell a 
drug for less than the copay amount.  
As before, assume that the resource still shows the names of therapeutic alternatives to brand-name drugs, and the prices the brand-
name and generic drugs at individual pharmacies. And if you click on a pharmacy, you can get it name, address, and phone number.  
And as before, assume that the alternatives were chosen based on reviews of available studies by an independent scientific advisory board 
unaffiliated with any drug manufacturers.”   
 
Link:  Concept-2 (Screenshot of hypothetical website) 
Q17. If this resource included such information on the co-pays for drugs in Medicare plans, how many times a day would you estimate you would 
discuss the cost with your Medicare patients? 
 Times per day ______ 
 
PLEASE ANSWER THESE FINAL QUESTIONS IN GENERAL: 
 
Q18. On a scale of 1 to 10, 1 meaning Not Important At All and 10 Extremely Important, how important would the following additional features of 
this resource be? 
 
Not 
Important 
at All 
1 2 3 4 5 6 7 8 9 
Extremely 
Important 
10 
a. If the resource 
included information 
on co-pays in ALL 
insurance plans, not 
just Medicare D  
          
 
Not 
Important 
at All 
1 2 3 4 5 6 7 8 9 
Extremely 
Important 
10 
b. If the resources 
were available as an 
app for a handheld 
device  
          
 
Q19. Roughly what percentage of your patients are: 
 Lower middle class/working poor   ______ 
 Middle class ______ 
 Upper class ______ 
 Speak Spanish as a first language   ______ 
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Thank you for completing our survey. Please fill out the information below to insure proper delivery of your 
honorarium. 
First Name:   
Last Name: 
Address:   
City: 
State: 
Zipcode: 
Phone: 
Fax:  
Email Address: 
 
(If not accepted through screening criteria, jumped to) 
Thank you for your interest in our Survey. We are sorry but you don't qualify at this time, we have you in our data 
base and will keep you in mind for future studies.  
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APPENDIX C 
 
Comparison of desirable features of current drug price transparency resources 
 
Price Transparency 
Therapeutic Alternative 
Recommendations 
  
based on 
 included 
 
Free 
Accessible 
to patients 
& providers 
up-to-date 
price info 
includes 
all retail 
pharmac
ies 
includes 1-
or-more  
on-line 
(mail 
order) 
pharmacies 
 
systematic 
reviews of 
clinical 
evidence 
objective, 
unbiased 
sources 
Consumer Reports Best Buy 
Drugs Y Y 
i   Y Y Y 
www.GoodRx.com Y Y Y Y Y Y ii ?iii Y iv 
www. Healthwarehouse.com Y Y Y  Y    
www.BidRx.com Y Y Y  Yv    
www.rxpricequotes.comvi Y Y Y Y     
www.Target.com Y Y vii  Y    
www.CVS.com Y Y viii  Y    
www.walmart.com Y Y ix      
 
 
i Consumer Reports lists prices that are based on nationwide average prices, based on past transactions. While it is unclear how up-to-date the 
prices are, they are static, as opposed to dynamic, information. No individual pharmacies are identified.  
ii GoodRx provides a ‘Savings Tips’ section for brand-name drugs, noting current or future generic availability. In addition, the brief description of 
each drug notes when other therapeutic alternatives may be available as a generic.  
iii It seems that GoodRx groups drugs by therapeutic or chemical type, rather than make recommendations regarding the efficiency of effectiveness 
of one drug compared to another.  
iv Similarly, it seems that GoodRx is not directly connected to, or currently receiving funding from, pharmaceutical companies in a manner that puts 
their recommendations regarding alternative drug choices in question. In fact their website is the best resource we have found to quickly 
determine if a new generic drug has yet become available on the national market.  
v As of 12/13/2013, the website www.BidRx.com listed multiple mail-order pharmacies, but very limited retail pharmacies.   The on-line registration 
process was onerous, and seemed to require corporate membership or affiliation to allow consumers to register, but a free referral code was sent 
to by email when requested of customer service.    
vi While the website www.rxpricequotes.com did provide some transparency into drug prices, the available prices for some generic drugs were far 
higher than those obtained through GoodRx.com or BidRx.com, for the same pharmacies.  
vii CVS, Target, and Walmart do provide lists of drugs that are available through their discount programs at certain fixed prices. But the price 
information is constrained by the limited list of drug products in their discount programs.  
viii CVS, Target, and Walmart do provide lists of drugs that are available through their discount programs at certain fixed prices. But the price 
information is constrained by the limited list of drug products in their discount programs.  
ix CVS, Target, and Walmart do provide lists of drugs that are available through their discount programs at certain fixed prices. But the price 
information is constrained by the limited list of drug products in their discount programs.  
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 The physicians in this sample reported that their practices serve predominantly 
middle class patients, with an estimated one-third being lower middle 
class/working poor.  Thirteen % of their patients speak Spanish. 
2 
Table 1. Practice Demographics 
© 2013 
Research by Medical Marketing Research, Inc. for Community Catalyst 
Respondents spend more than an hour a day addressing cost-related issues, 
including discussions with 43% (13 of 30) of their patients, on average. 
30 patients seen 
13 discussions/day  
67 min./day 
0
10
20
30
40
50
60
70
A B C
3 
A. Mean number of patients seen per day (S.D.=12.20) 
B. Mean number of discussions of drug costs with patients per day (S.D.=8) 
C. Mean number of minutes per day spent addressing drug cost related issues with 
patients, pharmacies or third parties. (S.D.=58.21) 
Table 2. Physician Daily Activities 
© 2013 
Research by Medical Marketing Research, Inc. for Community Catalyst 
 
Respondents estimate encountering situations of patient non-adherence due to 
cost issues over 50 times/month, for an average of twice a day.(Q4) 
26 times/month 
28 times/month 
0
10
20
30
40
Patient has not gotten a prescription filled
because of medication cost
Patient has taken less than the prescribed
dose because of medication cost
4 
Table 3. Medication Non-Adherence Due to Costs 
© 2013 
Research by Medical Marketing Research, Inc. for Community Catalyst 
 
Overall, half of the respondents find it difficult (6 or higher on a 10 point scale) to engage 
patients in discussions concerning the cost of the medications they prescribe, while half 
found it less or not difficult ( 5 or lower), yielding the bi-modal distribution below.  
“5.On a scale of 1 to 10, 1 meaning not at all difficult and 10 extremely difficult, how difficult do you find it to engage patients in discussion 
concerning the cost of the medication you prescribe?”  
 
12.5% 
10.0% 
12.5% 
10.0% 
5.0% 
7.5% 
12.5% 
17.5% 
10.0% 
2.5% 
0%
5%
10%
15%
20%
1 2 3 4 5 6 7 8 9 10
%
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p
o
n
d
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Mean = 5.2 
5 
Not at All Difficult Extremely Difficult 
Table 4. Difficulty of Discussing Rx Costs with Patients 
© 2013 
Research by Medical Marketing Research, Inc. for Community Catalyst 
  
When they do occur, discussions of drug costs with patients are initiated by 
doctors in nearly twice as many different as they are by patients.  
 
”6. When you talk with patients about the cost of their medications, how does the conversation get started?”  (open-ended question) 
 (2) 5.0% 
(3) 7.5% 
 (3) 7.5% 
 (3) 7.5% 
(4) 10.0% 
(5) 12.5% 
(6) 15.0% 
(7) 17.5% 
(13)32.5% 
0% 10% 20% 30% 40%
Patients usually bring it up
Patients start complaining about the cost of their meds
I ask if no generic, would higher copay strain you financially
I ask if they have Rx coverage
I ask if they know their copayment
I ask how well they know their Rx plan
I initiate the discussion
I ask if any problems getting or taking their meds.
I ask if they can afford their meds
% Respondents 
6 
Table 5. How Discussions of Rx Costs Begin 
© 2013 
Research by Medical Marketing Research, Inc. for Community Catalyst 
 
Local pharmacy prices, insurer formularies and drug company promotional materials are 
the most commonly available resources for answering patient questions about the cost of 
the medications doctors are prescribing.  
“7. What, if any, resources do you have available to you to answer patient questions concerning the cost of medications you are prescribing?” 
(open-ended question)  
5.0% 
5.0% 
5.0% 
7.5% 
7.5% 
10.0% 
10.0% 
20.0% 
20.0% 
30.0% 
0% 10% 20% 30%
EMR to access patients medical & insurance info
Nothing
My staff
Coupons, vouchers, & saving cards etc.
Free samples
Epocrates for cost estimates
Medication & Medicare websites/Internet
Brochures & flyers or cost  from drug companies/reps
Formulary information from insurance companies
Cost of drugs at local pharmacies/pharmacists
% Respondents 
7 
Table 6. Resources on Rx Costs Used by Physicians 
© 2013 
Research by Medical Marketing Research, Inc. for Community Catalyst 
Generics and drug samples are the most popular of many strategies used by 
respondents to lower the cost of medications for their patients. 
“8. What strategies do you currently use to lower the cost of medications for some or all  of your  patients?”  (open-ended question) 
5.0% 
5.0% 
7.5% 
7.5% 
12.5% 
15.0% 
17.5% 
17.5% 
40.0% 
60.0% 
0% 15% 30% 45% 60%
$4/$12 drug list
Split pills in half
Copay cards
Cost reduction cards
Vouchers
Make sure drug is on formulary
Patient assistance programs
Coupons/rebates
Free samples
Generic drugs
% Respondents 
8 
Table 7. Strategies to Lower Rx Costs for Patients 
© 2013 
Research by Medical Marketing Research, Inc. for Community Catalyst 
Eighty-three percent of respondents (33 of 40) reacted positively to 
Concept 1, while only 1 respondent  had a negative reaction.  
“9.In general, would you describe your reaction to this concept as positive, negative, neutral?” 
82.5% 
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9 
Table 8. Reaction to Model Drug Pricing Resource 
© 2013 
Research by Medical Marketing Research, Inc. for Community Catalyst 
“Recommendations of generic alternatives to brand-name drugs” was highly useful (8 or 
higher) to more than half of respondents, with another 32.5% rating it as useful (6 or 7).  
 
“10.Which of the following features, if any, do you like or find the most useful: recommendations of generic alternatives to brand-name drugs?”  
(not useful)        1....2....3....4....5....6....7....8....9....10          (very useful)  
5.0% 
2.5% 
0.0% 
2.5% 2.5% 
10.0% 
22.5% 
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17.5% 
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Mean = 7.28 
10 
Not Useful Very Useful 
Table 9a: What Resource Features Are Most Useful? 
© 2013 
Research by Medical Marketing Research, Inc. for Community Catalyst 
Price differences between brands and generics was rated as rather useful (8, 9 
or 10) by more than three fourths of all respondents (77.5%).   
“10. Which of the following features, if any, do you like or find the most useful:”  
“b. The difference between the prices of brand-name drugs and lower cost generic alternatives?” 
2.5% 
0.0% 0.0% 0.0% 
5.0% 
7.5% 7.5% 
30.0% 
27.5% 
20.0% 
0%
10%
20%
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Mean = 8.13 
11 
Not Useful Very Useful 
Table 9b. Comparison of Useful Features of the Resource 
© 2013 
Research by Medical Marketing Research, Inc. for Community Catalyst 
Exact price differences between pharmacies was rated as rather useful (8, 9, 10) by three 
fourths of all respondents, with a third of respondents (35%) rating it as high as possible.  
 
“10. Which of the following features, if any, do you like or find the most useful:”  
”c. The differences in exact prices for the same drug at different pharmacies?”  
 
0.0% 
2.5% 2.5% 
0.0% 
2.5% 
7.5% 
10.0% 
20.0% 20.0% 
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Mean = 8.30 
12 
Not Useful Very Useful 
Table 9c. Comparison of Features of the Resource 
© 2013 
Research by Medical Marketing Research, Inc. for Community Catalyst 
Nine other features were suggested, but none by more than a single respondent.  
2.5% 
2.5% 
2.5% 
2.5% 
2.5% 
2.5% 
2.5% 
2.5% 
2.5% 
2.5% 
A faster way to get PAs
Pharmacy address/telephone number
Differences in cost, even in the mail order Rx's
Ease of integration into EMR
Cost comparison between branded as well
Patients out of pocket cost based on whether pharmacy
participates in plan or not
Cost comparison of drugs in same class
RPh Advisor
Drug mnaufacturers
Number of days allowed per Rx % of Total Respondents 
13 
N=9 
Table 9d. Other Useful Features Suggested 
© 2013 
Research by Medical Marketing Research, Inc. for Community Catalyst 
Most respondents (70%) indicated there was nothing about Concept 1 they 
disliked. Some minor concern were shared by 10% or less of the respondents.  
 
“11.What if anything do you particularly dislike?” (open-ended question) 
2.5% 
2.5% 
2.5% 
2.5% 
2.5% 
2.5% 
2.5% 
2.5% 
7.5% 
10.0% 
70.0% 
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Other
Confusing
Pharmacies won't like price lowering comparison
Pharmacist may recommend cheaper but not equal Rx
Patients may have to drive all over to save a few cents
No incentivization for physician to perform this extra work
The process or steps to enroll
Price comparison
Too much information
Time consuming
Nothing
14 % Respondents 
Table 10. Features of Pricing Resource Disliked  
© 2013 
Research by Medical Marketing Research, Inc. for Community Catalyst 
Ninety percent of respondents indicated they would use this resource 
with some frequency (7 or higher).   
. 
“12. On a scale of 1 to 10, …  how often would you expect to use this resource?” 
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Mean = 7.78 
15 
Would Not Use at All Would Use it Frequently 
Table 11. How Often Would This Resource Be Used? 
© 2013 
Research by Medical Marketing Research, Inc. for Community Catalyst 
Resource was anticipated for use in multiple contexts – by physicians engaging 
with patients, by patients with other staff, or by patients acting independently.  
“13.  There are multiple ways this information can be shared with patients – through you personally, through your staff, by letting the patient 
access the information themselves.  Of the times you would use this resource,  what percent of the time do you think you would:” 
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Table 12. Who in the Practice Would Use this Resource? 
© 2013 
Research by Medical Marketing Research, Inc. for Community Catalyst 
Respondents predicted using the resource an average of 10 times per day; or  
9 times per day if Medicare copay information was also included.  
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Mean = 8.5 
S.D. = 6.79 
17 
A. If this resource were available to you, how many times per day would you estimate you might 
use it in some way in  discussing the cost of medication with your patients? 
 
B. If this resource included such information on the co-pays for drugs in Medicare plans, how 
many times a day would you estimate you would discuss the cost with your Medicare patients? 
Mean = 9.65 
S.D. = 9.14 
Table 13. How Often Per Day Would This Resource Be Used? 
© 2013 
Research by Medical Marketing Research, Inc. for Community Catalyst 
Most respondents (72.5%) predicted this resource would have a significant impact  
(7 or higher) on time addressing cost issues from patients, pharmacies and payers. 
“15. On a scale of 1 to 10, ... what impact would you expect your use of this resource to have on  the amount of time you and your staff spend 
addressing cost issues from patients and third parties like pharmacies and Payors:”  
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No Impact at All A Great Impact 
Table 14a.  Impact of This Resource on Physician/Staff Time 
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Eighty percent of respondents predicted this resource could significantly  
impact (7 or higher) price-related non-adherence (i.e. failures to refill.) 
“15. On a scale of 1 to 10, 1 meaning no impact at all and 10 a great impact, what impact would you expect your use of this resource to have on 
b. the frequency with which patients do not get their prescriptions filled due to price issues?” 
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No Impact at All A Great Impact 
Table 14b.  Impact of This Resource on Rx Fills 
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Seventy percent of respondents predicted resource could significantly impact  
(7 or higher) price-related non-adherence (i.e. failure to take medication.) 
 
“15. On a scale of 1 to 10, … what impact would you expect your use of this resource to have on  the frequency with which patients do not take 
their medication as directed due to cost issues:”  
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Table 14c. Impact of This Resource on Taking Medication 
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Nearly 9 out of 10 respondents found this resource at least moderately useful 
(7 or higher) to easily engage patients in discussing drug costs and affordability.  
“16. How useful would this resource be in terms of making it easier to engage with your patients in discussions of cost and 
affordability of medications?” 
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Not Useful at All Extremely Useful 
Table 15. Impact of This Resource on Patient Engagement 
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“Eighty-five percent of respondents felt inclusion of co-pay amounts for ALL insurance 
plans in the resource would be at least moderately important (7 or higher) and more 
than half (57.5%) felt it was very important (9 or higher.) 
“18.How important would the following additional features of this resource be: if the resource included information on co-pays in ALL insurance 
plans, not just Medicare D” 
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Not Important at All Extremely Important 
Table 16. Importance of Copay Cost Information 
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Three fourths of all respondents felt putting the resource on a handheld device 
was rather important (7 or higher); half felt it to be very important (9 or higher).  
“18. How important would the following additional features of this resource be: If the resources was available as an app for a 
handheld device? “     
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Not Important at All Extremely Important 
Table 17: Importance of an App for this Resource 
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